Maxalt and Exostosis - a phase IV clinical study of FDA data

Summary:

Exostosis is reported as a side effect among people who take Maxalt (rizatriptan benzoate), especially for people who are female, 50-59 old, also take Neurontin, and have Breast cancer.

The phase IV clinical study analyzes which people have Exostosis when taking Maxalt. It is created by eHealthMe based on reports of 11,566 people who have side effects when taking Maxalt from the FDA, and is updated regularly.

What is Maxalt?

Maxalt has active ingredients of rizatriptan benzoate. It is often used in migraine. eHealthMe is studying from 12,754 Maxalt users. Check the latest studies of Maxalt.

What is Exostosis?

Exostosis (formation of new bone on the surface of a bone) is found to be associated with 1,084 drugs and 931 conditions by eHealthMe. Check the latest studies of Exostosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 14, 2026

11,566 people reported to have side effects when taking Maxalt.
Among them, 47 people (0.41%) have Exostosis.

Among these 47 people:

What is the gender of people who have Exostosis when taking Maxalt? *

female: 95.45 %
male: 4.55 %

What is the age of people who have Exostosis when taking Maxalt? *

What are other drugs people take besides Maxalt? *

What are other side effects people have besides Exostosis? *

Joint Pain: 30 people, 63.83%
Hypoaesthesia (reduced sense of touch or sensation): 26 people, 55.32%
Weakness: 26 people, 55.32%
Blood Glucose Increased: 25 people, 53.19%
Bone Disorder: 24 people, 51.06%
Intervertebral Disc Protrusion (spinal disc protrusion): 24 people, 51.06%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 24 people, 51.06%
Oedema Peripheral (superficial swelling): 24 people, 51.06%
Nausea (feeling of having an urge to vomit): 23 people, 48.94%
Gastric Ulcer (stomach ulcer): 23 people, 48.94%

What are the existing conditions these people have? *

Breast Cancer: 21 people, 44.68%
Neoplasm Malignant (cancer tumour): 20 people, 42.55%
Breast Cancer Metastatic: 20 people, 42.55%
Discomfort: 20 people, 42.55%
Ovarian Cancer (cancer of ovary): 20 people, 42.55%
Hot Flush (sudden feelings of heat): 20 people, 42.55%
Granulocyte Count Decreased: 19 people, 40.43%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 6 people, 12.77%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 5 people, 10.64%
Immunodeficiency Common Variable: 5 people, 10.64%

* Approximation only. Some reports may have incomplete information.

Do you take Maxalt and have Exostosis?

- Check whether Exostosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Maxalt:

Maxalt (12,754 reports)

Exostosis treatments and more:

Exostosis (13,639 reports)

Browse all side effects of Maxalt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Exostosis:

Exostosis (1,084 drugs)

Browse all the conditions that are associated with Exostosis:

Exostosis (931 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rizatriptan benzoate (the active ingredients of Maxalt) and Maxalt (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.